SelectQuote, Inc. Q4 2026 Earnings Call Summary

Strategic Inflection and Operational Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management is prioritizing cash flow generation and leverage reduction over top-line growth, viewing fiscal 2027 as a critical inflection point for equity value accretion.

The Healthcare Services division reached a milestone as the company's largest revenue contributor, exiting fiscal 2026 at a $50 million annual EBITDA run rate.

Senior segment profitability remained durable with 26% adjusted EBITDA margins despite a challenging Medicare Advantage environment characterized by carrier benefit shifts and varying origination volumes.

Operating cash flow improved by $44 million year-over-year, driven by increased scale at the Olathe, Kansas distribution facility and a maturing SelectRx member base.

The company identified over $30 million in annualized expense improvements through AI-enabled enrollment tools, automated revenue processes, and organizational rightsizing.

Strategic prudence in Medicare Advantage growth for fiscal 2027 is a deliberate choice to match market dynamics as carriers work toward their own 3% to 4% operating margin targets.

Technology investments, specifically the new custom-built pharmacy management system, have already delivered 30% efficiency gains on shipments compared to legacy locations.

Fiscal 2027 Outlook and Strategic Assumptions

Fiscal 2027 revenue is projected to decline 14% at the midpoint, reflecting a 10% to 15% drop in MA approved policies and a similar decline in Healthcare Services due to the Inflation Reduction Act.

Operating cash flow is expected to approximately double to $60 million plus in fiscal 2027, with free cash flow targeted at approximately $50 million.

Healthcare Services margins are projected to approximately double in fiscal 2027 as a higher percentage of scripts are routed through the more efficient Kansas facility.

Management assumes the upcoming Annual Enrollment Period (AEP) will remain dynamic, with a return to 'responsible growth' for carriers potentially delayed until plan year 2028.

The company plans to reduce funding costs and aggregate leverage through a combination of debt repayment from expanding EBITDA and potential future refinancing of its 12% cost-of-capital debt.

The Inflation Reduction Act (IRA) is creating material revenue headwinds in Healthcare Services, though management notes it does not significantly impact EBITDA due to the geography of reimbursements.

Medicare Advantage market disruption continues via plan terminations and benefit pullbacks, necessitating a shift toward Special Needs Plans (SNPs) where the company over-indexes.

Customer acquisition costs in the Term Life insurance market remain competitive, leading management to maintain a measured outlook despite recent performance gains.

A change in a key carrier partner's strategic marketing investment contributed to a 4% revenue decline in the Senior segment during fiscal 2026.